EyePoint Announces $25.5 Million Financing, Looks to Launch Two Ophthalmic Products in 2019

June 29, 2018: By Jon Swedien

EyePoint PharmaceuticalsEyePoint Pharmaceuticals announced June 25 that its stockholders have approved a second tranche of growth capital under a securities purchase agreement for $25.5 million.

The Massachusetts company (formerly pSivida) also said it plans to launch DEXYCU and YUTIQ in the first half of 2019.

DEXYCU is a US FDA-approved treatment for pain following ocular surgery. YUTIQ is a three-year treatment candidate for non-infectious uveitis with a Nov. 5 target action date.

Essex Woodland (EW) Healthcare Partners, Rosalind Advisors, and another accredited investor make up the second tranche investors.

EyePoint’s gross proceeds upon closing will total $35 million, including $9.5 million from a March 2018 equity financing with EW Healthcare Partners, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales